Therapeutic Human Polyclonals Inc.
Therapeutic Human Polyclonals Inc., a California-based biotherapeutics company with a subsidiary in Germany, has developed a unique transgenic mammalian platform to create human antibodies. THP is the first company to create transgenic rabbits with a human antibody repertoire for producing both monoclonal and polyclonal antibody therapeutics. Initial disease targets include the antibiotic-resistant staphylococcus and enterococcus bacteria, viral infections and various human cancers.
Working with the founders, Roland Buelow, Ph.D., and Wim Van Schooten, Ph.D., Research Corporation Technologies provided the initial funding and incubation to develop and commercialize THP's next-generation human antibody therapies. In November 2002, SangStat Medical Corp. (acquired by Genzyme Corporation in Cambridge, Mass.) joined RCT in continuing to fund development of THP's novel antibody platform.
Roche, the world's largest biotechnology company, completed its acquisition of THP for $56.5 million March 29, 2007.
Inventors/Founders
Roland Buelow, Ph.D., Wim van Schooten, Ph.D.
